Dapagliflozin meets diabetes endpoints

Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) said oral dapagliflozin as an add-on to glimepiride met the primary endpoint vs. placebo plus glimepiride in a Phase...